US20020064860A1 - Method for purifying adenoviruses - Google Patents

Method for purifying adenoviruses Download PDF

Info

Publication number
US20020064860A1
US20020064860A1 US09/991,080 US99108001A US2002064860A1 US 20020064860 A1 US20020064860 A1 US 20020064860A1 US 99108001 A US99108001 A US 99108001A US 2002064860 A1 US2002064860 A1 US 2002064860A1
Authority
US
United States
Prior art keywords
adenovirus
hydroxyapatite
concentration
sample pool
sodium chloride
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US09/991,080
Inventor
Susan Cannon-Carlson
Collette Cutler
Gary Vellekamp
Marcio Voloch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Sharp and Dohme Corp
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Priority to US09/991,080 priority Critical patent/US20020064860A1/en
Publication of US20020064860A1 publication Critical patent/US20020064860A1/en
Assigned to SCHERING CORPORATION reassignment SCHERING CORPORATION ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: VOLOCH, MARCIO, CANNON-CARLSON, SUSAN, CUTLER, COLLETTE, VELLEKAMP, GARY
Priority to US11/326,275 priority patent/US7393631B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011Details
    • C12N2710/10011Adenoviridae
    • C12N2710/10311Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10351Methods of production or purification of viral material

Definitions

  • This invention relates to methods for purifying adenoviruses from a contaminated sample using a hydroxyapatite chromatographic medium.
  • Adenoviruses are preferred in many gene therapy applications as a vector to deliver the therapeutic gene.
  • the cultivation and purification of adenoviruses containing therapeutic genes, such as tumor suppressor genes and other biological response modifiers, have become increasingly important for gene therapy and vaccine development.
  • larger quantities of purified viral vectors are needed to deliver the therapeutic gene in treatment.
  • the relatively large diameter (approximately 80 nm) and fragile structure of adenoviruses make their purification challenging using conventional methods, e.g., cesium chloride density centrifugation and gel filtration chromatography, which have scale limitations. Chromatographic protocols for purifying live adenoviruses are known, e.g., see U.S. Pat.
  • This invention provides a method for purifying biologically active adenoviruses from a contaminated sample using a hydroxyapatite medium under conditions which permit the adenovirus to reversibly bind to the hydroxyapatite while contaminants are passed.
  • the present purification method greatly reduces the level of contaminants and empty adenovirus capsids from adenovirus samples first purified by conventional purification methods.
  • the concentration of sodium chloride present in buffers used throughout the method is at least 150 mM to prevent the adenovirus from irreversibly binding to the hydroxyapatite. Lower sodium chloride concentrations can cause adenovirus to irreversibly bind to the hydroxyapatite.
  • a method for purifying biologically active adenovirus from a contaminated sample pool includes the steps of contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the biologically active adenovirus to the hydroxyapatite, followed by eluting the bound biologically active adenovirus from the hydroxyapatite.
  • the sample pool used in a method of the invention contains a buffered solution including about 50 mM sodium phosphate pH about 7.5, about 400 mM sodium chloride, about 2% sucrose, about 2 mM MgCl 2 , and about 10% glycerol.
  • This invention provides a method for purifying biologically active adenoviruses from incomplete virions and various viral and non-viral protein contaminants in a sample using a hydroxyapatite medium.
  • contaminant means an undesirable impurity in a sample containing adenovirus, e.g., an empty capsid (which is an immature viral particle lacking viral DNA and containing precursors to mature viral proteins such as pVIII, and is not capable of adhering to or penetrating a suitable cell), a nucleic acid molecule, a free viral protein (e.g., viral proteins III or hexon), a non-viral protein (e.g., host or media derived proteins such as BSA, which is a common cell culture component in mammalian systems).
  • An advantage of the present purification method is that the hydroxyapatite medium used under salt and buffer conditions in accordance with the invention reduces the level of incomplete virus particles in the adenovirus sample.
  • the term “purifying”, and grammatical variations thereof, when used in reference to a method of the present invention, means at least a 50% reduction of total contaminants, in particular, free viral and non-viral proteins, in an adenovirus sample, as quantitated by silver stain SDS gel chromatography, over an adenovirus sample that is purified using a conventional purification method (i.e., a purification method known in the art other than the use of hydroxyapatite, e.g., DEAE chromatography) before a purification step of the present invention.
  • a conventional purification method i.e., a purification method known in the art other than the use of hydroxyapatite, e.g., DEAE chromatography
  • the reduction in total contaminants is at least 80%. Most preferably the reduction in total contaminants is 90% or better.
  • the reduction in empty capsids is at least 50%, preferably 75%, more preferably 80%, and most preferably 85% or better, as quantitated using reverse phase HPLC by measuring a viral protein precursor to adenovirus protein VIII (“pVIII”) [see Galibert et al., Gene 6: 1 (1979) and Herisse et al., Nucl. Acids Res. 8: 2173 (1980)], which is not found in mature, infectious adenoviruses. It is noted that a method of the present invention that is scaled up for commercial production may result in slightly lower percent reductions, preferably not more than 5 to 10% lower reductions.
  • Any adenovirus can be purified by the present invention, whether it is a wild type, mutant, or recombinant.
  • Type 2 and type 5 adenoviral vectors are preferred.
  • Adenoviruses can be prepared and cultivated according to methods known in the art, e.g., see Wills et al., Hum. Gene Ther. 5: 1079-1088 ( 1994 ), Hughye et al., Hum. Gene Ther. 6: 1403-1416 (1995), and laboratory manuals as described, supra.
  • Adenoviruses purified by the present method are “infectious”, which means they comprise a multi-subunit capsid that encapsulates a nucleic acid molecule and can interact with a receptor on a suitable cell to result in a transfer of the nucleic acid from the adenovirus into the cell.
  • An “empty capsid” is an incomplete virus particle that is not infectious, e.g., a virus particle that has a capsid, but lacks a nucleic acid molecule.
  • An adenovirus used in this invention is preferably replication deficient such that the virus cannot reproduce after it infects a cell. These viruses are well-known in the art.
  • An adenovirus can include a heterologous nucleic acid sequence e.g., a therapeutic gene, that can be transferred from the viral vector to a host cell for use in gene therapy.
  • a therapeutic gene is a DNA sequence that encodes a particular sequence of amino acids which comprise all or part of one or more proteins and that has a desired therapeutic effect.
  • the therapeutic gene may or may not include regulatory DNA sequences, such as promoter sequences, which determine, for example, the conditions under which the gene is expressed.
  • a therapeutic gene replaces an absent or mutated gene that causes an increase in pathological cell growth or proliferation of cells.
  • a therapeutic gene can exhibit a corresponding therapeutic effect by, e.g., remaining extrachromosomal such that the gene is expressed by the cell from the extrachromosomal location, or incorporating into the host cell genome in a recombination event with the endogenous gene.
  • Methods for introducing heterologous nucleic acid sequences into a viral vector are well known in the art.
  • Examples of therapeutic genes include tumor-suppressor genes, e.g., Rb and mutants thereof, p53 and mutants thereof, p21 and mutants thereof, DCC, NF-1, Wilm's tumor, NM 23, BRCA-1, BRCA-2, BRUSH-1, p56, H-NUC, thyroid hormone receptor gene, retenoic acid receptor gene, genes encoding p130, p107, and p85.
  • Other gene replacement or supplementation strategies include adenosine deaminase (ADA), thymidine kinase (TK), genes encoding various cytokines, e.g., ⁇ -interferon, ⁇ -interferon, IL-2, IL-10 and hormones.
  • a therapeutic gene also includes DNA encoding a ribozyme, i.e., a DNA construct that encodes an RNA enzyme which binds and destroys the RNA of selected positively-acting growth regulatory genes, such as oncogenes or proto-oncogenes including, but not limited to: c-myc, c-fos, c-jun, c-myb, c-ras, KC and JE; and growth factor receptor genes including but not limited to: epidermal growth factor, platelet derived growth factor, transferrin and insulin.
  • a ribozyme i.e., a DNA construct that encodes an RNA enzyme which binds and destroys the RNA of selected positively-acting growth regulatory genes, such as oncogenes or proto-oncogenes including, but not limited to: c-myc, c-fos, c-jun, c-myb, c-ras, KC and JE; and growth factor receptor genes including
  • the therapeutic gene is a tumor suppressor gene, e.g., Rb, p53, BRUSH-1, p56, BRCA-1,BRCA-2, p16 or p21, or a mutant gene thereof.
  • the adenoviral vector harbors the p53 gene (e.g., the adenoviral vector is ACN53).
  • adenovirus is efficiently purified from empty capsids and contaminants using a hydroxyapatite medium provided the minimum concentration of sodium chloride is at least 150 mM in buffered solutions used throughout the method.
  • the minimum sodium chloride concentration prevents the virus from irreversibly binding to the hydroxyapatite medium.
  • buffered solutions used in this invention contain from about 350 to 450 mM sodium chloride. It is noted that concentrations of 500 mM or greater sodium chloride can cause the virus to become unstable, and preferably are not used in a method of the invention.
  • salts for sodium chloride if desired, at suitable concentrations (having similar conductivity), including monovalent ionic and cationic salts, e.g., KCl or NH 4 Cl, or divalent anionic and cationic salts, e.g., Na 2 SO 4 or (NH 4 ) 2 SO 4 .
  • monovalent ionic and cationic salts e.g., KCl or NH 4 Cl
  • divalent anionic and cationic salts e.g., Na 2 SO 4 or (NH 4 ) 2 SO 4 .
  • a “buffered solution” is an aqueous solution which contains sodium chloride and a suitable buffer to maintain the pH of the solution between about 6.8 to 9.0, preferably between about pH 7.0 to 8.0, most preferably between about pH 7.4 to 7.6. In a specific embodiment of the invention, the pH is 7.5. Buffers having a pKa within the desired pH range are preferred. A buffered solution does not cause an adenovirus to irreversibly bind to a hydroxyapatite medium.
  • Buffered solutions are used, e.g., in a sample pool containing the adenovirus, to equilibrate and wash (equilibration and wash buffers) the hydroxyapatite medium, and to elute (elution buffers) the adenovirus bound to the hydroxyapatite.
  • buffers examples include phosphate, MES, HEPES, MOPS, Borate, TRIS, BES, ADA, ACES, PIPES, MOPSO, BIS-TRIS PROPANE, BES, TES, DIPSO, TAPSO, TRIZMA, HEPPSO, POPSO, TEA, EPPS, TRICINE, GLYCYLGLYCINE, BICINE, TAPS, and the like.
  • Buffered solutions used in this invention can also be formulated with a stabilizing or tonicity-adjusting agent, e.g., polyhydroxy hydrocarbons such as glycerol, disacharrides such as sucrose, divalent metal salt stabilizers such as magnesium, zinc and calcium salt, and monovalent metal salt stabilizers such as potassium, sodium, lithium and cesium salts.
  • a stabilizing or tonicity-adjusting agent e.g., polyhydroxy hydrocarbons such as glycerol, disacharrides such as sucrose, divalent metal salt stabilizers such as magnesium, zinc and calcium salt, and monovalent metal salt stabilizers such as potassium, sodium, lithium and cesium salts.
  • aqueous buffered solutions that can be used in a method of this invention are described in International Patent Publication No. WO 99/41416, which is incorporated herein by reference in its entirety.
  • a buffer used in the invention can contain less than 1% glycerol to about 20% glycerol and/or less than 1% to about 5% sucrose.
  • the concentrations of glycerol and sucrose can be about 5 to 10% and about 0.5 to 2% respectively.
  • sample pool is a buffered solution that contains adenovirus and a contaminant, which may have been prepared from a conventional purification method, from which the further purification of the adenovirus is desired.
  • a sample pool is formulated with additional stabilizing or tonicity-adjusting agents, as described above.
  • a sample pool contains about 50 mM NaPO 4 (pH 7.5), 400 mM NaCl and 10% glycerol.
  • a sample pool typically contains a concentration range of adenovirus from about 1 ⁇ 10 9 to about 1 ⁇ 10 14 per ml.
  • the sample pool is formulated with one or more stabilizing agents, such as glycerol and sucrose, as described above, particularly when higher concentrations of virus are used.
  • a sample pool can be prepared from a cell lysate.
  • cells such as 293 cells, infected with adenovirus are removed from the growth environment and their cell membranes disrupted, e.g., by physiological or chemical means, according to methods well known in the art (see Wills et al., supra and Hughye et al., supra).
  • the cell lysate containing the adenovirus is preferably first subjected to one or more conventional chromatography methods to provide a virus sample pool, which is further purified according to a method of the invention.
  • a cell lysate containing adenovirus can be processed to enzymatically degrade DNA and RNA followed by a conventional purification method, including anion-exchange chromatography, gel filtration (size-exclusion) chromatography, hydrophobic interaction chromatography or immobilized metal affinity chromatograpy. Combinations of these methods can be used if desired, e.g., see U.S. Pat. No. 5,837,520, which is incorporated herein by reference in its entirety.
  • the conventional method used is an anion-exchange chromatography.
  • the conventional chromatography methods remove most of the cellular debris and some of the unassembled viral proteins and non-viral protein contaminants, however, a variety of contaminants, e.g., BSA, viral proteins such as free hexon, and incomplete virions lacking viral DNA (empty capsids), may remain in the samples. Surprisingly, these contaminants are efficiently removed by a purification method using hydroxyapatite, which improves the purity, resolution and quality of adenovirus in the sample compared with the conventional viral purification methods.
  • contaminants e.g., BSA, viral proteins such as free hexon, and incomplete virions lacking viral DNA (empty capsids)
  • the hydroxyapatite medium used in a method of the invention can be prepared as a chromatographic column according to conventional methods well known in the art.
  • an HA column can be prepared for traditional (gravity) column chromatography, fast performance chromatography or high pressure liquid chromatography using radial or axial flow fluidized bed columns, as desired.
  • the hydroxyapatite medium is preferably washed and equilibrated using a buffered aqueous solution, as described supra, before purifying the adenovirus according to this invention.
  • an equilibration buffer used to equilibrate the hydroxyapatite contains about 50 mM NaPO 4 (pH 7.5), 400 mM NaCl, 2% sucrose, 10% glycerol and 2 mM MgCl 2 .
  • the column can be equilibrated until the eluent reaches the pH and conductivity of the buffer, typically about five to ten bed volumes.
  • the sample pool is contacted with the hydroxyapatite media to permit the adenovirus to reversibly bind to the hydroxyapatite and the contaminants to pass through the media, thus separating the contaminants from the virus.
  • the hydroxyapatite column which contains the bound adenovirus, is washed with a wash buffer, which can be the same buffer used to equilibrate (equilibration buffer) the hydroxyapatite.
  • a wash buffer which can be the same buffer used to equilibrate (equilibration buffer) the hydroxyapatite.
  • the adenovirus can be eluted from the hydroxyapatite using a gradient elution or step elution to phosphate in equilibration buffer (elution buffer).
  • the adenovirus can be eluted using, e.g., about a 5 to 30 bed volume gradient to, e.g., 200 mM sodium phosphate in equilibration buffer.
  • a 10 bed volume gradient is used.
  • the elution buffer can be equilibration buffer containing preferably about 150 to 250 mM phosphate.
  • the present method is performed in a temperature range from about 5 to 30° C., more preferably from about 15 to 27° C. Most preferably the method is performed at room temperature, e.g., about 20 to 27° C. It is noted that at less than about 15° C., the virus may begin to irreversibly bind to the column depending on the salt conditions and presence of stabilizing agents.
  • room temperature e.g., about 20 to 27° C.
  • the non-viral proteins and high molecular weight contaminants elute in the spent charge and wash of the column.
  • the empty capsids bind more tightly to hydroxyapatite than the biologically active virus, and thus empty capsids do not elute from the hydroxyapatite with the biologically active virus.
  • the fractions off the column can be analyzed by UV absorbance, Resource Q analytical HPLC and rp-HPLC, and used to make a single pool of purified biologically active adenovirus.
  • This Example demonstrates a purification method of the present invention using hydroxyapatite in comparison with a conventional virus purification method.
  • Adenoviruses containing the p53 gene (ACN53), cultivated from mammalian 293 cells, were captured from cell lysates using a conventional DEAE anion-exchange chromatography method.
  • the sample pool from the DEAE contained a 31 kDa protein (pVIII), which corresponds to a precursor of adenoviral protein VIII (hexon associated protein).
  • the DEAE pool was prepared as a sample pool for use in a purification method of the invention by buffering to 50 mM NaPO 4 (pH 7.5), 400 mM NaCl, and 5 to 10% glycerol. Hydroxyapatite columns (0.5 ⁇ 10 cm, 0.5 ⁇ 20 cm, and 1.6 ⁇ 15 cm), equilibrated into 50 mM NaPO 4 (pH 7.5), 400 mM NaCl, 2% sucrose and 2 mM MgCl 2 , were prepared by packing.
  • the buffered DEAE pool was applied to the hydroxyapatite column, washed with equilibration buffer as described, and the adenovirus eluted using a gradient elution to 600 mM phosphate in equilibration buffer or by step elution with 250 mM phosphate in equilibration buffer.
  • Reverse-phase HPLC and size-exclusion HPLC showed that in the hydroxyapatite eluate compared with the DEAE pool there was a significant reduction in incomplete virus particles and free viral proteins, e.g., at least 75% reductions in pVIII, reduction of free penton to undetectable levels and 40% reduction in free hexon.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Solid-Sorbent Or Filter-Aiding Compositions (AREA)
  • Saccharide Compounds (AREA)
  • Filtering Materials (AREA)

Abstract

Methods for purifying adenoviruses from a contaminated sample using a hydroxyapatite medium are provided. Sodium chloride concentrations present in buffers used throughout the method are at least 150 mM to prevent the adenovirus from irreversibly binding to the hydroxyapatite. Levels of contaminants and empty adenovirus capsids from samples purified by conventional purification techniques are further reduced to provide a highly pure adenovirus preparation.

Description

    FIELD OF INVENTION
  • This invention relates to methods for purifying adenoviruses from a contaminated sample using a hydroxyapatite chromatographic medium. [0001]
  • BACKGROUND OF THE INVENTION
  • Adenoviruses are preferred in many gene therapy applications as a vector to deliver the therapeutic gene. The cultivation and purification of adenoviruses containing therapeutic genes, such as tumor suppressor genes and other biological response modifiers, have become increasingly important for gene therapy and vaccine development. As studies of gene therapy progress to clinical trials, larger quantities of purified viral vectors are needed to deliver the therapeutic gene in treatment. The relatively large diameter (approximately 80 nm) and fragile structure of adenoviruses make their purification challenging using conventional methods, e.g., cesium chloride density centrifugation and gel filtration chromatography, which have scale limitations. Chromatographic protocols for purifying live adenoviruses are known, e.g., see U.S. Pat. No. 5,837,520, however, small amounts of contaminating proteins and incomplete virus particles, e.g., empty capsids, are found in virus preparations using these protocols. This is a significant problem since empty capsids and other protein contaminants can be immunogenic in vivo. Therefore, it would be advantageous to have an effective process that provides a sample of highly purified viable virus, while significantly reducing levels of incomplete virus particles. Improved virus purity without sacrifice to virus yield would be beneficial in large-scale adenovirus production. [0002]
  • Thus, there is a need in the art for improved purification methods for adenoviruses that can resolve live virus from incomplete viral particles and other contaminating proteins in the viral preparation. The present invention addresses this and other needs in the art. [0003]
  • SUMMARY OF THE INVENTION
  • This invention provides a method for purifying biologically active adenoviruses from a contaminated sample using a hydroxyapatite medium under conditions which permit the adenovirus to reversibly bind to the hydroxyapatite while contaminants are passed. The present purification method greatly reduces the level of contaminants and empty adenovirus capsids from adenovirus samples first purified by conventional purification methods. The concentration of sodium chloride present in buffers used throughout the method is at least 150 mM to prevent the adenovirus from irreversibly binding to the hydroxyapatite. Lower sodium chloride concentrations can cause adenovirus to irreversibly bind to the hydroxyapatite. [0004]
  • It is an advantage of a method of the invention that empty capsids, i.e., incomplete viral particles, which are not infectious and thus not useful for gene therapy or other applications, are separated from intact viruses. Thus, a highly purified and resolved, infectious adenovirus sample is provided. [0005]
  • Thus, a method for purifying biologically active adenovirus from a contaminated sample pool is provided, which includes the steps of contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the biologically active adenovirus to the hydroxyapatite, followed by eluting the bound biologically active adenovirus from the hydroxyapatite. [0006]
  • In a specific embodiment, the sample pool used in a method of the invention contains a buffered solution including about 50 mM sodium phosphate pH about 7.5, about 400 mM sodium chloride, about 2% sucrose, about 2 mM MgCl[0007] 2, and about 10% glycerol.
  • DETAILED DESCRIPTION OF THE INVENTION
  • In accordance with the present invention, there may be employed molecular biology, microbiology, or recombinant DNA techniques within the ordinary skill of the art to prepare, grow and cultivate viruses used in a method of the invention. Such techniques are explained fully in the literature. See, e.g., Sambrook, Fritsch & Maniatis, Molecular Cloning: A Laboratory Manual, Second Edition (1989), Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York; DNA Cloning: A Practical Approach, Volumes I and II (D. N. Glover ed. 1985); Oligonucleotide Synthesis [M. J. Gait ed. (1984)]; Nucleic Acid Hybridization [B. D. Hames & S. J. Higgins eds. (1985)]; Transcription And Translation [B. D. Hames & S. J. Higgins, eds. (1984)]; Animal Cell Culture [R. I. Freshney, ed. (1986)]; Immobilized Cells And Enzymes [IRL Press, (1986)]; A Practical Guide To Molecular Cloning [B. Perbal (1984)]; Current Protocols in Molecular Biology, John Wiley & Sons, Inc., F. M. Ausubel et al., eds., 1994; Virology: A laboratory manual. Academic Press, New York, (Burleson, ed., 1992). [0008]
  • This invention provides a method for purifying biologically active adenoviruses from incomplete virions and various viral and non-viral protein contaminants in a sample using a hydroxyapatite medium. [0009]
  • The term “contaminant” means an undesirable impurity in a sample containing adenovirus, e.g., an empty capsid (which is an immature viral particle lacking viral DNA and containing precursors to mature viral proteins such as pVIII, and is not capable of adhering to or penetrating a suitable cell), a nucleic acid molecule, a free viral protein (e.g., viral proteins III or hexon), a non-viral protein (e.g., host or media derived proteins such as BSA, which is a common cell culture component in mammalian systems). An advantage of the present purification method is that the hydroxyapatite medium used under salt and buffer conditions in accordance with the invention reduces the level of incomplete virus particles in the adenovirus sample. [0010]
  • The term “purifying”, and grammatical variations thereof, when used in reference to a method of the present invention, means at least a 50% reduction of total contaminants, in particular, free viral and non-viral proteins, in an adenovirus sample, as quantitated by silver stain SDS gel chromatography, over an adenovirus sample that is purified using a conventional purification method (i.e., a purification method known in the art other than the use of hydroxyapatite, e.g., DEAE chromatography) before a purification step of the present invention. Preferably the reduction in total contaminants is at least 80%. Most preferably the reduction in total contaminants is 90% or better. The reduction in empty capsids is at least 50%, preferably 75%, more preferably 80%, and most preferably 85% or better, as quantitated using reverse phase HPLC by measuring a viral protein precursor to adenovirus protein VIII (“pVIII”) [see Galibert et al., Gene 6: 1 (1979) and Herisse et al., Nucl. Acids Res. 8: 2173 (1980)], which is not found in mature, infectious adenoviruses. It is noted that a method of the present invention that is scaled up for commercial production may result in slightly lower percent reductions, preferably not more than 5 to 10% lower reductions. [0011]
  • Any adenovirus can be purified by the present invention, whether it is a wild type, mutant, or recombinant. Type 2 and type 5 adenoviral vectors are preferred. Adenoviruses can be prepared and cultivated according to methods known in the art, e.g., see Wills et al., Hum. Gene Ther. 5: 1079-1088 ([0012] 1994), Hughye et al., Hum. Gene Ther. 6: 1403-1416 (1995), and laboratory manuals as described, supra.
  • Adenoviruses purified by the present method are “infectious”, which means they comprise a multi-subunit capsid that encapsulates a nucleic acid molecule and can interact with a receptor on a suitable cell to result in a transfer of the nucleic acid from the adenovirus into the cell. [0013]
  • An “empty capsid” is an incomplete virus particle that is not infectious, e.g., a virus particle that has a capsid, but lacks a nucleic acid molecule. [0014]
  • An adenovirus used in this invention is preferably replication deficient such that the virus cannot reproduce after it infects a cell. These viruses are well-known in the art. [0015]
  • An adenovirus can include a heterologous nucleic acid sequence e.g., a therapeutic gene, that can be transferred from the viral vector to a host cell for use in gene therapy. A “therapeutic gene” is a DNA sequence that encodes a particular sequence of amino acids which comprise all or part of one or more proteins and that has a desired therapeutic effect. The therapeutic gene may or may not include regulatory DNA sequences, such as promoter sequences, which determine, for example, the conditions under which the gene is expressed. Preferably, a therapeutic gene replaces an absent or mutated gene that causes an increase in pathological cell growth or proliferation of cells. Once in a host cell, a therapeutic gene can exhibit a corresponding therapeutic effect by, e.g., remaining extrachromosomal such that the gene is expressed by the cell from the extrachromosomal location, or incorporating into the host cell genome in a recombination event with the endogenous gene. Methods for introducing heterologous nucleic acid sequences into a viral vector are well known in the art. [0016]
  • Examples of therapeutic genes include tumor-suppressor genes, e.g., Rb and mutants thereof, p53 and mutants thereof, p21 and mutants thereof, DCC, NF-1, Wilm's tumor, NM 23, BRCA-1, BRCA-2, BRUSH-1, p56, H-NUC, thyroid hormone receptor gene, retenoic acid receptor gene, genes encoding p130, p107, and p85. Other gene replacement or supplementation strategies include adenosine deaminase (ADA), thymidine kinase (TK), genes encoding various cytokines, e.g., γ-interferon, α-interferon, IL-2, IL-10 and hormones. A therapeutic gene also includes DNA encoding a ribozyme, i.e., a DNA construct that encodes an RNA enzyme which binds and destroys the RNA of selected positively-acting growth regulatory genes, such as oncogenes or proto-oncogenes including, but not limited to: c-myc, c-fos, c-jun, c-myb, c-ras, KC and JE; and growth factor receptor genes including but not limited to: epidermal growth factor, platelet derived growth factor, transferrin and insulin. Most preferably the therapeutic gene is a tumor suppressor gene, e.g., Rb, p53, BRUSH-1, p56, BRCA-1,BRCA-2, p16 or p21, or a mutant gene thereof. In a specific embodiment, the adenoviral vector harbors the p53 gene (e.g., the adenoviral vector is ACN53). [0017]
  • Surprisingly, it has been discovered that adenovirus is efficiently purified from empty capsids and contaminants using a hydroxyapatite medium provided the minimum concentration of sodium chloride is at least 150 mM in buffered solutions used throughout the method. The minimum sodium chloride concentration prevents the virus from irreversibly binding to the hydroxyapatite medium. More preferably, buffered solutions used in this invention contain from about 350 to 450 mM sodium chloride. It is noted that concentrations of 500 mM or greater sodium chloride can cause the virus to become unstable, and preferably are not used in a method of the invention. One skilled in the art can substitute other salts for sodium chloride, if desired, at suitable concentrations (having similar conductivity), including monovalent ionic and cationic salts, e.g., KCl or NH[0018] 4Cl, or divalent anionic and cationic salts, e.g., Na2SO4 or (NH4)2SO4.
  • A “buffered solution” is an aqueous solution which contains sodium chloride and a suitable buffer to maintain the pH of the solution between about 6.8 to 9.0, preferably between about pH 7.0 to 8.0, most preferably between about pH 7.4 to 7.6. In a specific embodiment of the invention, the pH is 7.5. Buffers having a pKa within the desired pH range are preferred. A buffered solution does not cause an adenovirus to irreversibly bind to a hydroxyapatite medium. Buffered solutions are used, e.g., in a sample pool containing the adenovirus, to equilibrate and wash (equilibration and wash buffers) the hydroxyapatite medium, and to elute (elution buffers) the adenovirus bound to the hydroxyapatite. [0019]
  • Examples of buffers that can be used in the invention include phosphate, MES, HEPES, MOPS, Borate, TRIS, BES, ADA, ACES, PIPES, MOPSO, BIS-TRIS PROPANE, BES, TES, DIPSO, TAPSO, TRIZMA, HEPPSO, POPSO, TEA, EPPS, TRICINE, GLYCYLGLYCINE, BICINE, TAPS, and the like. Phosphate buffer in a concentration of about 25 to 100 mM, more preferably about 50 mM is preferred. [0020]
  • Buffered solutions used in this invention can also be formulated with a stabilizing or tonicity-adjusting agent, e.g., polyhydroxy hydrocarbons such as glycerol, disacharrides such as sucrose, divalent metal salt stabilizers such as magnesium, zinc and calcium salt, and monovalent metal salt stabilizers such as potassium, sodium, lithium and cesium salts. These additional agents are particularly useful when the sodium chloride concentration in the sample pool is greater than 350 mM. [0021]
  • Formulations of aqueous buffered solutions that can be used in a method of this invention are described in International Patent Publication No. WO 99/41416, which is incorporated herein by reference in its entirety. For example, depending on the virus concentration, a buffer used in the invention can contain less than 1% glycerol to about 20% glycerol and/or less than 1% to about 5% sucrose. At 1×10[0022] 14 or less virus particles per ml, the concentrations of glycerol and sucrose can be about 5 to 10% and about 0.5 to 2% respectively.
  • A “sample pool” is a buffered solution that contains adenovirus and a contaminant, which may have been prepared from a conventional purification method, from which the further purification of the adenovirus is desired. Preferably, a sample pool is formulated with additional stabilizing or tonicity-adjusting agents, as described above. In one embodiment a sample pool contains about 50 mM NaPO[0023] 4 (pH 7.5), 400 mM NaCl and 10% glycerol.
  • A sample pool typically contains a concentration range of adenovirus from about 1×10[0024] 9 to about 1×1014 per ml. Preferably, the sample pool is formulated with one or more stabilizing agents, such as glycerol and sucrose, as described above, particularly when higher concentrations of virus are used.
  • A sample pool can be prepared from a cell lysate. For example, cells such as 293 cells, infected with adenovirus are removed from the growth environment and their cell membranes disrupted, e.g., by physiological or chemical means, according to methods well known in the art (see Wills et al., supra and Hughye et al., supra). The cell lysate containing the adenovirus is preferably first subjected to one or more conventional chromatography methods to provide a virus sample pool, which is further purified according to a method of the invention. For example, a cell lysate containing adenovirus can be processed to enzymatically degrade DNA and RNA followed by a conventional purification method, including anion-exchange chromatography, gel filtration (size-exclusion) chromatography, hydrophobic interaction chromatography or immobilized metal affinity chromatograpy. Combinations of these methods can be used if desired, e.g., see U.S. Pat. No. 5,837,520, which is incorporated herein by reference in its entirety. Preferably, the conventional method used is an anion-exchange chromatography. [0025]
  • The conventional chromatography methods remove most of the cellular debris and some of the unassembled viral proteins and non-viral protein contaminants, however, a variety of contaminants, e.g., BSA, viral proteins such as free hexon, and incomplete virions lacking viral DNA (empty capsids), may remain in the samples. Surprisingly, these contaminants are efficiently removed by a purification method using hydroxyapatite, which improves the purity, resolution and quality of adenovirus in the sample compared with the conventional viral purification methods. [0026]
  • The hydroxyapatite medium used in a method of the invention can be prepared as a chromatographic column according to conventional methods well known in the art. For example, an HA column can be prepared for traditional (gravity) column chromatography, fast performance chromatography or high pressure liquid chromatography using radial or axial flow fluidized bed columns, as desired. [0027]
  • The hydroxyapatite medium is preferably washed and equilibrated using a buffered aqueous solution, as described supra, before purifying the adenovirus according to this invention. In a specific embodiment, an equilibration buffer used to equilibrate the hydroxyapatite contains about 50 mM NaPO[0028] 4 (pH 7.5), 400 mM NaCl, 2% sucrose, 10% glycerol and 2 mM MgCl2. The column can be equilibrated until the eluent reaches the pH and conductivity of the buffer, typically about five to ten bed volumes.
  • After the hydroxyapatite is washed, the sample pool is contacted with the hydroxyapatite media to permit the adenovirus to reversibly bind to the hydroxyapatite and the contaminants to pass through the media, thus separating the contaminants from the virus. [0029]
  • The hydroxyapatite column, which contains the bound adenovirus, is washed with a wash buffer, which can be the same buffer used to equilibrate (equilibration buffer) the hydroxyapatite. After washing the adenovirus-bound hydroxyapatite column, the adenovirus can be eluted from the hydroxyapatite using a gradient elution or step elution to phosphate in equilibration buffer (elution buffer). If gradient elution is desired, the adenovirus can be eluted using, e.g., about a 5 to 30 bed volume gradient to, e.g., 200 mM sodium phosphate in equilibration buffer. Preferably, a 10 bed volume gradient is used. If step elution is desired, the elution buffer can be equilibration buffer containing preferably about 150 to 250 mM phosphate. [0030]
  • The present method is performed in a temperature range from about 5 to 30° C., more preferably from about 15 to 27° C. Most preferably the method is performed at room temperature, e.g., about 20 to 27° C. It is noted that at less than about 15° C., the virus may begin to irreversibly bind to the column depending on the salt conditions and presence of stabilizing agents. One having ordinary skill in the art can optimize conditions in accordance with the invention as desired. [0031]
  • The non-viral proteins and high molecular weight contaminants elute in the spent charge and wash of the column. The empty capsids bind more tightly to hydroxyapatite than the biologically active virus, and thus empty capsids do not elute from the hydroxyapatite with the biologically active virus. The fractions off the column can be analyzed by UV absorbance, Resource Q analytical HPLC and rp-HPLC, and used to make a single pool of purified biologically active adenovirus. [0032]
  • EXAMPLE
  • This Example demonstrates a purification method of the present invention using hydroxyapatite in comparison with a conventional virus purification method. [0033]
  • Adenoviruses containing the p53 gene (ACN53), cultivated from mammalian 293 cells, were captured from cell lysates using a conventional DEAE anion-exchange chromatography method. The sample pool from the DEAE contained a 31 kDa protein (pVIII), which corresponds to a precursor of adenoviral protein VIII (hexon associated protein). [0034]
  • The DEAE pool was prepared as a sample pool for use in a purification method of the invention by buffering to 50 mM NaPO[0035] 4 (pH 7.5), 400 mM NaCl, and 5 to 10% glycerol. Hydroxyapatite columns (0.5×10 cm, 0.5×20 cm, and 1.6×15 cm), equilibrated into 50 mM NaPO4 (pH 7.5), 400 mM NaCl, 2% sucrose and 2 mM MgCl2, were prepared by packing. The buffered DEAE pool was applied to the hydroxyapatite column, washed with equilibration buffer as described, and the adenovirus eluted using a gradient elution to 600 mM phosphate in equilibration buffer or by step elution with 250 mM phosphate in equilibration buffer.
  • Reverse-phase HPLC and size-exclusion HPLC showed that in the hydroxyapatite eluate compared with the DEAE pool there was a significant reduction in incomplete virus particles and free viral proteins, e.g., at least 75% reductions in pVIII, reduction of free penton to undetectable levels and 40% reduction in free hexon. [0036]
  • Densitometric analyses of silver stained SDS-PAGE demonstrated that hydroxyapatite also efficiently removed total non-viral protein contaminants, i.e., an 80 to 90% reduction of proteins which are resolved from intact virions in CsCI gradients (e.g., 70 to 85% reductions in BSA), and high molecular weight complex proteins, i.e., a 25% reduction of unidentified proteins cosedimenting with the virus in CsCI gradients. In experiments where BSA was spiked into the feed to the column, the BSA passed through the column without binding to the hydroxyapatite under the buffer conditions described, demonstrating that the hydroxyapatite chromatography efficiently resolves BSA from the sample. [0037]
  • Polymerase chain reaction analyses of nucleic acids present in the eluate showed an 8-fold reduction in short fragments and a 100-fold reduction in medium fragments. [0038]
  • Thus, use of hydroxyapatite chromatography under the buffer and salt conditions described to purify adenovirus samples provides an adenovirus sample having great resolution for use in gene therapy or other virus applications requiring high purity. [0039]
  • The present invention has been described herein with reference to certain preferred embodiments and an example. Since obvious variations will appear to those skilled in the art, the invention is not to be considered limited thereto, but only by the claims which follow. [0040]

Claims (19)

What is claimed is:
1. A method for purifying adenovirus from contaminants in a sample pool, comprising:
contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the adenovirus to the hydroxyapatite; and
eluting the bound adenovirus from the hydroxyapatite.
2. The method of claim 1, wherein the sample pool comprises sodium chloride in a concentration of from about 150 to 500 mM.
3. The method of claim 1, wherein the hydroxyapatite chromatographic medium is equilibrated with a buffer comprising sodium chloride at a concentration of from about 150 to 500 mM before the step of contacting the sample pool with the hydroxyapatite.
4. The method of claim 1, further comprising the step of washing the hydroxyapatite with a buffer comprising sodium chloride in a concentration of 150 to 500 mM, wherein the hydroxyapatite comprises an adenovirus bound thereto.
5. The method of claim 1, wherein the adenovirus is eluted using a buffer comprising sodium chloride in a concentration from about 150 mM to 500 mM.
6. The method of claim 1 wherein the sodium chloride concentration in a buffer used in the method is from about 350 mM to 450 mM.
7. The method of claim 1, wherein the sample pool is prepared from an eluate of a conventional chromatography medium.
8. The method of claim 7 wherein the conventional chromatography medium is:
an anion exchange resin;
an immobilized metal ion affinity resin;
a size exclusion chromatography resin; or
a medium used in hydrophobic interaction chromatography.
9. The method of claim 1, wherein the eluting step is a gradient elution to 600 mM phosphate.
10. The method of claim 1, wherein the eluting step is a step elution with 250 mM phosphate.
11. The method of claim 1, wherein a buffer used in the method comprises glycerol or sucrose.
12. The method of claim 1, wherein the concentration of adenovirus in the sample pool is equal to or less than 1×1014 particles per ml.
13. The method of claim 1, wherein the adenovirus comprises a therapeutic gene.
14. The method of claim 1, wherein the adenovirus is ACN53.
15. The method of claim 1, wherein the adenovirus comprises a nucleic acid sequence from the p53 gene or from the p21 gene.
16. A method of claim 1, which reduces the concentration of a contaminant in the sample pool by at least 80%.
17. A method of claim 1, which reduces the concentration of empty capsids by at least 75%.
18. A method of claim 1, which reduces the concentration of BSA by at least 70%.
19. A method for purifying adenovirus from contaminants in sample pool, comprising:
contacting the sample pool with a hydroxyapatite chromatographic medium to reversibly bind the adenovirus to the hydroxyapatite;
washing the adenovirus-bound hydroxyapatite with a buffered solution; and
eluting the bound adenovirus from the hydroxyapatite, wherein the sample pool is a buffered solution comprising about 50 mM sodium phosphate pH about 7.5, about 400 mM sodium chloride, about 2% sucrose, about 2 mM MgCl2, and about 10% glycerol, and the concentration of total contaminants is reduced by at least 80%.
US09/991,080 2000-11-29 2001-11-16 Method for purifying adenoviruses Abandoned US20020064860A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
US09/991,080 US20020064860A1 (en) 2000-11-29 2001-11-16 Method for purifying adenoviruses
US11/326,275 US7393631B2 (en) 2000-11-29 2006-01-05 Method for purifying adenoviruses

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25382300P 2000-11-29 2000-11-29
US09/991,080 US20020064860A1 (en) 2000-11-29 2001-11-16 Method for purifying adenoviruses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US11/326,275 Continuation US7393631B2 (en) 2000-11-29 2006-01-05 Method for purifying adenoviruses

Publications (1)

Publication Number Publication Date
US20020064860A1 true US20020064860A1 (en) 2002-05-30

Family

ID=22961846

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/991,080 Abandoned US20020064860A1 (en) 2000-11-29 2001-11-16 Method for purifying adenoviruses
US11/326,275 Expired - Lifetime US7393631B2 (en) 2000-11-29 2006-01-05 Method for purifying adenoviruses

Family Applications After (1)

Application Number Title Priority Date Filing Date
US11/326,275 Expired - Lifetime US7393631B2 (en) 2000-11-29 2006-01-05 Method for purifying adenoviruses

Country Status (7)

Country Link
US (2) US20020064860A1 (en)
EP (1) EP1337627B1 (en)
AT (1) ATE455168T1 (en)
AU (1) AU2002232443A1 (en)
DE (1) DE60141081D1 (en)
ES (1) ES2337768T3 (en)
WO (1) WO2002044348A2 (en)

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270041A1 (en) * 2004-12-13 2006-11-30 Howe John A Cell lines for production of replication-defective adenovirus
US20080107629A1 (en) * 2006-09-29 2008-05-08 Canji, Inc. Methods and compositions for gene therapy
WO2009138544A1 (en) 2008-05-16 2009-11-19 Proyecto De Biomedicina Cima, S.L. Self-inactivating helper adenoviruses for the production of high-capacity recombinant adenoviruses
WO2009147271A2 (en) 2008-06-04 2009-12-10 Proyecto De Biomedicina Cima, S.L. System for packaging high-capacity adenoviruses
US20100008889A1 (en) * 2005-12-12 2010-01-14 Canji, Inc. Adenoviral expression vectors
GB2474354A (en) * 2009-10-07 2011-04-13 Hoya Corp Virus purification method using sintered hydroxyapatite particles
US11333642B2 (en) 2016-10-25 2022-05-17 Regeneran Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
US11369896B2 (en) 2016-08-16 2022-06-28 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
US11884698B2 (en) 2018-07-02 2024-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
US12070502B2 (en) 2014-10-09 2024-08-27 Regeneron Pharmaceuticals, Inc. Process for reducing subvisible particles in a pharmaceutical formulation

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7319002B2 (en) 2001-08-08 2008-01-15 The Trustees Of The University Of Pennsylvania Method for purification of viral vectors having proteins which bind sialic acid
EP1718738A2 (en) 2004-02-23 2006-11-08 Crucell Holland B.V. Virus purification methods
ATE412737T1 (en) 2005-04-11 2008-11-15 Crucell Holland Bv VIRUS CLEANING WITH ULTRAFILTRATION
EP1736538A1 (en) 2005-06-21 2006-12-27 Cytos Biotechnology AG Process for the preparative purification of virus-like-particles (VLPs)
CA2742474C (en) 2008-11-03 2016-05-31 Crucell Holland B.V. Method for the production of adenoviral vectors
MX2012004222A (en) 2009-10-15 2012-06-08 Crucell Holland Bv Method for the purification of adenovirus particles.
AU2010305768B2 (en) 2009-10-15 2015-05-14 Crucell Holland B.V. Process for adenovirus purification from high cell density cultures
AU2011214262B2 (en) 2010-02-15 2015-05-21 Crucell Holland B.V. Method for the production of Ad26 adenoviral vectors
JP6898535B1 (en) * 2020-06-16 2021-07-07 HOYA Technosurgical株式会社 Virus purification method using apatite column

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141863A (en) * 1986-08-11 1992-08-25 Mitsui Toatsu Chemicals, Incorporated Purification procedure of TPA from crude preparations
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07173189A (en) 1993-12-17 1995-07-11 Masashi Kosakai Method for using hydroxyapatite chromatography in two stages in presence of ligand
JPH08188599A (en) 1995-01-09 1996-07-23 Toagosei Co Ltd Separation and purification of immunoglobulin y antibody
WO1997008298A1 (en) * 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
JPH09169794A (en) 1995-12-22 1997-06-30 Mitsubishi Materials Corp Separation of proteins
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
ATE550429T1 (en) 1996-11-20 2012-04-15 Crucell Holland Bv ADENOVIRUS COMPOSITIONS AVAILABLE THROUGH AN IMPROVED PRODUCTION AND PURIFICATION PROCESS
US6261823B1 (en) 1996-12-13 2001-07-17 Schering Corporation Methods for purifying viruses
CA2320419C (en) 1998-02-17 2011-02-08 Schering Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
JP2000262280A (en) 1999-03-18 2000-09-26 Asahi Optical Co Ltd Purification of virus or viral antigen and prodution of vaccine

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5141863A (en) * 1986-08-11 1992-08-25 Mitsui Toatsu Chemicals, Incorporated Purification procedure of TPA from crude preparations
US5496926A (en) * 1992-01-19 1996-03-05 Yeda Research And Development Co. Ltd. Process of preparing a soluble LDL receptor
US5723438A (en) * 1992-01-19 1998-03-03 Yeda Research And Development Co. Ltd. Method of antiviral use of soluble LDL receptor
US20020004226A1 (en) * 1992-01-19 2002-01-10 Yeda Research And Developmemt Co. Ltd. Soluble LDL receptor, its production and use
US6365713B1 (en) * 1992-01-19 2002-04-02 Yeda Research And Development Company, Limited Soluble LDL receptor, its production and use
US5837520A (en) * 1995-03-07 1998-11-17 Canji, Inc. Method of purification of viral vectors

Cited By (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060270041A1 (en) * 2004-12-13 2006-11-30 Howe John A Cell lines for production of replication-defective adenovirus
US7851218B2 (en) 2004-12-13 2010-12-14 Schering Corporation Cell lines for production of replication-defective adenovirus
US20100008889A1 (en) * 2005-12-12 2010-01-14 Canji, Inc. Adenoviral expression vectors
US8398968B2 (en) 2005-12-12 2013-03-19 Canji Inc. Adenoviral expression vectors
US20080107629A1 (en) * 2006-09-29 2008-05-08 Canji, Inc. Methods and compositions for gene therapy
WO2009138544A1 (en) 2008-05-16 2009-11-19 Proyecto De Biomedicina Cima, S.L. Self-inactivating helper adenoviruses for the production of high-capacity recombinant adenoviruses
WO2009147271A2 (en) 2008-06-04 2009-12-10 Proyecto De Biomedicina Cima, S.L. System for packaging high-capacity adenoviruses
GB2474354A (en) * 2009-10-07 2011-04-13 Hoya Corp Virus purification method using sintered hydroxyapatite particles
US12070502B2 (en) 2014-10-09 2024-08-27 Regeneron Pharmaceuticals, Inc. Process for reducing subvisible particles in a pharmaceutical formulation
US11850535B2 (en) 2016-08-16 2023-12-26 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
US11571636B2 (en) 2016-08-16 2023-02-07 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
US11369896B2 (en) 2016-08-16 2022-06-28 Regeneron Pharmaceuticals, Inc. Methods for quantitating individual antibodies from a mixture
US11680930B2 (en) 2016-10-25 2023-06-20 Regeneron Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
US11333642B2 (en) 2016-10-25 2022-05-17 Regeneran Pharmaceuticals, Inc. Methods and systems for chromatography data analysis
US12042538B2 (en) 2017-09-19 2024-07-23 Regeneron Pharmaceuticals, Inc. Methods of reducing particle formation and compositions formed thereby
US11884698B2 (en) 2018-07-02 2024-01-30 Regeneron Pharmaceuticals, Inc. Systems and methods for preparing a polypeptide from a mixture

Also Published As

Publication number Publication date
AU2002232443A1 (en) 2002-06-11
ATE455168T1 (en) 2010-01-15
EP1337627A2 (en) 2003-08-27
WO2002044348A3 (en) 2002-11-07
ES2337768T3 (en) 2010-04-29
EP1337627B1 (en) 2010-01-13
DE60141081D1 (en) 2010-03-04
US20060105456A1 (en) 2006-05-18
WO2002044348A2 (en) 2002-06-06
US7393631B2 (en) 2008-07-01

Similar Documents

Publication Publication Date Title
US7393631B2 (en) Method for purifying adenoviruses
JP3379758B2 (en) Enhancement of transfection efficiency of nucleic acid using aqueous solution containing isopropanol
US5837520A (en) Method of purification of viral vectors
AU779267B2 (en) Method for separating viral particles
Urthaler et al. Improved downstream process for the production of plasmid DNA for gene therapy
AU2004249199B2 (en) Method for purifying virus
EP0948601A1 (en) Methods for purifying viruses
JP2002536992A (en) Method for obtaining purified virus preparation
WO1998022588A9 (en) An improved method for the production and purification of adenoviral vectors
AU5361798A (en) An improved method for the production and purification of adenoviral vectors
EP0969090A1 (en) Rapid and simple process for isolation of circular nucleic acids
WO2005111059A2 (en) Process for the reduction of endotoxins
US6617443B2 (en) Method for removing endotoxins
Meyer et al. Bacteriophage fd gene II-protein. I. Purification, involvement in RF replication, and the expression of gene II.
Stillman et al. An adenovirus protein associated with the ends of replicating DNA molecules
EP3248984A2 (en) Method for purifying protein, fusion protein containing peptide tag, and production method thereof
Spector et al. Polyadenylic acid on poliovirus RNA: IV. Poly (U) in replicative intermediate and double-stranded RNA
EP3919613B1 (en) Enhanced purification of adeno-associated virus to more effectively remove contaminating dna
EP3239164A2 (en) Method for purifying target protein
JP2002179697A (en) Method for removing endotoxin from basic protein
Ferreira et al. Evaluation of novel chromatographic prototypes for supercoiled plasmid DNA polishing
WO1998023630A1 (en) Matrix for rapid purification of nucleic acids
Vasi et al. Ion-Exchange Chromatography Based Strategies for Purification of Viral Vectors
Eriksson et al. Purification of adenoviral vectors using anion exchange chromatography
HERZER J. VASI¹, R. MORENWEISER², K. ERIKSSON¹," R. LEMMENS¹

Legal Events

Date Code Title Description
AS Assignment

Owner name: SCHERING CORPORATION, NEW JERSEY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CANNON-CARLSON, SUSAN;CUTLER, COLLETTE;VELLEKAMP, GARY;AND OTHERS;REEL/FRAME:013226/0330;SIGNING DATES FROM 20011030 TO 20011031

STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION